Showing 8611-8620 of 9285 results for "".
- Sienna Biopharmaceuticals: Promising Topline Results for SNA-001 for Hair Removalhttps://practicaldermatology.com/news/sienna-biopharmaceuticals-promising-topline-results-for-sna-001-for-hair-removal/2459899/Topline results from the pivotal trial of Sienna Biopharmaceuticals’ SNA-001 show that the topical agent in conjunction with an 810nm diode laser was statistically superior compared to vehicle plus laser. In the study involving 65 male and female patients with white, gray, blonde, light red
- FDA Grants 510(k) Clearance to Laseroptek's PicoLOhttps://practicaldermatology.com/news/fda-grants-510k-clearance-to-laseropteks-picolo/2459903/Laseroptek’s PicoLO picosecond Nd:YAG laser is now U.S. Food and Drug Administration-cleared for marketing in dermatology and general and plastic surgery. According to the company, PicoLO generates high peak power and consistent picosecond pul
- Lutronic Genius RF Microneedling Platform Cleared by FDAhttps://practicaldermatology.com/news/lutronic-genius-rf-microneedling-platform-cleared-by-fda/2459905/Lutronic has received FDA clearance of the Lutronic Genius™ platform for radiofrequency microneedling. The company says the device transmits energy more precisely into the skin. The Lutronic Intelligent Care
- New from BD: Prefillable Glass Syringe for Viscous Solutionshttps://practicaldermatology.com/news/new-from-bd-prefillable-glass-syringe-for-viscous-solutions/2459910/BD (Becton, Dickinson and Company) has presented BD Hylok,its new glass pre-fillable syringe for the administration of viscous solutions such as hyaluronic acid dermal fillers, at Pharmapack 2019. BD Hylokis also the first glass pre-fillab
- Key West Bans Sunscreens with Oxybenzone and Octinoxatehttps://practicaldermatology.com/news/key-west-bans-sunscreens-with-oxybenzone-and-octinoxate/2459911/Following Hawaii’s lead, Florida’s Key West City Commission voted to ban the sale of products that contain oxybenzone or octinoxate — two chemicals in sunscreen that have been shown to wash off and potentially damage coral reefs. The ban takes effect in January 2021. Fir
- 2019 Residents of Distinction Return from Caribbean Dermatology Symposiumhttps://practicaldermatology.com/news/2019-residents-of-distinction-return-from-caribbean-dermatology-symposium/2459919/Five dermatology residents have just returned from the 18th Annual Caribbean Dermatology Symposium, held in Grand Cayman Island. Their participation was sponsored by Beiersdorf Inc., as part of the dermMentors™ Resident of Distinction Award™ program. The reside
- Remembering a Legend: Vic A Narurkar, MDhttps://practicaldermatology.com/news/remembering-a-legend-vic-a-narurkar-md/2459921/The dermatology community lost a true rock star with the sudden passing of Vic A Narurkar MD, FAAD in late January. Loved by so many, Dr. Narurkar was the Founder of the Bay Area Laser Institute in San Francisco and a past president of the American Society of Cosmetic Derma
- New “Own Your Look” Botox Campaign Targets Millennialshttps://practicaldermatology.com/news/new-own-your-look-botox-campaign-targets-millennials/2459923/Allergan’s new direct-to-consumer campaign, "Own Your Look," aims to address the most common misconceptions around Botox Cosmetic (onabotulinumtoxinA) among millennials, namely the fear of looking frozen. This is the first campaign from the brand created specifically to ad
- Keloids May Up Breast Cancer Riskhttps://practicaldermatology.com/news/keloids-may-up-breast-cancer-risk/2459925/Keloids may be associated with an increased risk breast cancer, particularly among African Americans, a new study suggests. The research team hypothesized African American women with a history of keloids would reflect a population of breast cancer patients with aggressive tumors and poor
- Dermatologists Call for Changes to Off-label Coverage Decisionshttps://practicaldermatology.com/news/dermatologists-call-for-changes-to-off-label-coverage-decisions/2459926/Dermatologists report major inconsistencies in Medicare Reimbursement Policy for off-label prescriptions and are now calling for an appeal process for cases where coverage is denied. Researchers from several institutions, including the Perelman School of Medicine at the University of Pennsylvania